Combination assay for serum tumor markers in patients with hepatic carcinoma

Table 1 Comparison serum alpha-fetoprotein, carbohydrate antibody19-9 and carcinoembryonic antigen in patients with hepatic solid space occupying lesions (x^-± s)

Grouping	n	AFP (μg/L)	CA19-9 (KU/L)	CEA (μg/L)
1 BHSSOL	30	11.07 ± 4.30	28.43 ± 15.76	10.49 ± 6.93
2 SHC	30	15.23 ± 13.13	231.20 ± 196.64	27.08 ± 13.35
3 PNHCC	30	14.03 ± 8.13	169.67 ± 140.08	19.27 ± 8.67
4 PHCC	30	320.65 ± 180.12	23.73 ± 12.91	10.73 ± 3.94

Notes: The comparison of AFP levels between group 4 and groups 1, 2, and 3: P < 0.01; among groups 1, 2, and 3: P > 0.05. CA 19-9 levels in groups 2 and 3 were higher than those in groups 1 and 4: P < 0.01; between group 2 and 3 and between group 1 and 4: P > 0.05. CEA levels in groups 2 and 3 were higher than those in groups 1 and 4 (P < 0.01); between group 2 and 3 and between group 1 and 4: P > 0.05. AFP, alpha-fetoprotein; BHSSOL, benign HSSOL; CA19-9, carbohydrate antibody 19-9; CEA, carcinoembryonic antigen; HSSOL, hepatic solid space occupying lesion; PHCC, primary hepatocellular carcinoma; PNHCC, primary non-hepatocellular carcinoma; SHC, secondary hepatic carcinoma

Table 2 Serum alpha-fetoprotein and carbohydrate antibody19-9 + carcinoembryonic antigen in patients with hepatic solid space occupying lesions

Grouping	No. of cases	AFP		CA19-9 + CEA
		Positive	Negative	Positive	Negative
BHSSOL	30	0	30	0	30
SHC	30	3	27	30	0
PNHCC	30
Biliary cell cancer	29	0	29	29	0
Mixed cancer	1	1	0	1	0
PNCC	30	30	0	0	30